Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16595289 | 0.84 | NR1H2 (0.41) | NR1H2NR1H3ALDH1A1HTT | |
| SCHEMBL17996474 | 0.83 | KCNN4 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16595779 | 0.81 | PSEN1 (0.39) | HTR1DHTR1BPSEN1PSEN2APH1B | |
| SCHEMBL16595182 | 0.80 | SMN1; SMN2 (0.36) | NR1H2NR1H3SLC6A4SLC6A3 | |
| SCHEMBL29443104 | 0.75 | KMT2A (0.47) | HTR1DHTR1BPSEN1PSEN2APH1B | |
| SCHEMBL1340597 | 0.75 | KMT2A (0.47) | HTR1DHTR1BPSEN1PSEN2APH1B | |
| SCHEMBL16595782 | 0.73 | HTR1D (0.38) | HTR1DHTR1BPSEN1PSEN2APH1B | |
| SCHEMBL10192246 | 0.72 | ACHE (0.41) | HTR1DHTR1BPSEN1PSEN2APH1B | |
| SCHEMBL16595796 | 0.71 | DPP9 (0.36) | HTR1DHTR1BPSEN1PSEN2APH1B | |
| SCHEMBL14825712 | 0.70 | DPP8 (0.36) | HTR1DHTR1BNR1H2PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARM INC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | HTR1D 4738/4885HTR1B 3909/4885NR1H2 495/4885 |
| US-20160229830-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | HTR1D 4738/4885HTR1B 3909/4885NR1H2 495/4885 |
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | HTR1D 4738/4885HTR1B 3909/4885NR1H2 495/4885 |
| US-20190263775-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | HTR1D 4738/4885HTR1B 3909/4885NR1H2 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.